Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PREVACID

« Back to Dashboard
Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Novartis. and is included in six NDAs. It is available from eight suppliers. There are five patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in PREVACID is lansoprazole; naproxen. There are fifty-two drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for Tradename: PREVACID

Suppliers / Packagers: see list49

Pharmacology for Tradename: PREVACID

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors

Clinical Trials for: PREVACID

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
Status: Completed Condition: Stomach Ulcer

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
Status: Completed Condition: Esophagitis; Reflux

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain
Status: Withdrawn Condition: Chest Pain; Gastrointestinal Reflux Disease

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Status: Completed Condition: Bioavailability

Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Status: Not yet recruiting Condition: Pediatric Gastroesophageal Reflux Disease

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions
Status: Completed Condition: Healthy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
CAPSULE, DELAYED REL PELLETS;ORAL020406-001May 10, 1995RXNo<disabled><disabled>
Takeda Pharms Usa
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002RXNo7,399,485*PED<disabled>Y<disabled>
Takeda Pharms Na
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PREVACID

Drugname Dosage Strength RLD Submissiondate
lansoprazoleDelayed-release Orally Disinte15 mg and 30 mgPrevacid12/27/2006
lansoprazoleDelayed-release Pellets/Capsul15 mg and 30 mgPrevacid12/5/2005
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn